Measuring Parkinson's Disease Progression

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

October 18, 2019

Study Completion Date

October 19, 2019

Conditions
Parkinson's Disease
Interventions
DRUG

Levodopa

"At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above."

Trial Locations (1)

63110

Washington University School of Medicine, Movement Disorders Center, St Louis

All Listed Sponsors
collaborator

The Michael J. Fox Foundation for Parkinson's Research

UNKNOWN

lead

Kevin J. Black, MD

OTHER

NCT03205956 - Measuring Parkinson's Disease Progression | Biotech Hunter | Biotech Hunter